Table 1.
Clinical data and antidiabetic treatment of study population at baseline (visit 0)
| Variable | Patients N. (Total = 128) | Value-% |
|---|---|---|
| Clinical parameters | ||
| Male | 74 | 57.8 |
| Age (median; range) | 70 (40–91) | – |
| Smoker | 42 | 32 |
| Hypertension | 105 | 82 |
| Dyslipidemia | 88 | 68.8 |
| CAD | 32 | 25 |
| Heart failure | 25 | 19.5 |
| Stroke | 7 | 5.5 |
| CKD (eGRF < 60 ml/min) | 46 | 35.9 |
| Microalbuminuria (>30 mg/l) | 23 | 18 |
| Neuropathy | 17 | 13.3 |
| Retinopathy | 33 | 25.8 |
| Antidiabetic treatment | ||
| Monotherapy | 15 | 11.7 |
| Multi-therapya | 113 | 88.3 |
| Metformin | 104 | 81.3 |
| SU | 24 | 18.5 |
| Insulin | 42 | 32.3 |
| SGLT2-I | 33 | 25.4 |
| DPP4-I | 32 | 24.6 |
| GLP-1 RA | 42 | 32.3 |
| Pioglitazone | 14 | 10.8 |
CAD coronary artery disease, CKD chronic kidney disease, eGFR estimated Glomerular Filtration Rate, SU sulfonylureas, SGLT2i sodium glucose cotransporter 2 inhibitors, DPP4i dipeptidyl peptidase IV inhibitors, GLP-1 RA glucagon-like peptide-1 receptor agonists
a97 out of 113 patients on anti-diabetic polytherapy were in metformin in addition of another class-drug